Clinical Trials Logo

Clinical Trial Summary

Using the UHR-OCT and HD-OCT to evaluate early postoperative changes in patients with diagnosis preretinal membrane after successfully performed pars-plana vitrectomy and membrane peeling with two different types of dyes.


Clinical Trial Description

Surgical procedures performed are pars-plana vitrectomy and membrane peeling with or without cataract extraction and IOL implantation. The type of the dyes is randomized. The study is designed to include a total of tweny cases (10 cases with ICG and 10 cases with Membrane blue)

Main outcome measures are:

UHR-OCT, HD-OCT distance and near visual acuity and contrast sensitivity amsler grid secondary outcome measures are: OCT Stratus 3000 and visual field. Clinical examinations: preoperative, and follow-up examinations after 1 week, 1 months, 3 months, 6 months and 12 months. ;


Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic


Related Conditions & MeSH terms


NCT number NCT00437593
Study type Interventional
Source The Ludwig Boltzmann Institute of Retinology and Biomicroscopic Laser Surgery
Contact
Status Completed
Phase N/A
Start date September 2005
Completion date May 2008

See also
  Status Clinical Trial Phase
Recruiting NCT04968756 - Evaluating the Safety of the SPECTRALIS CENTAURUS Device N/A
Recruiting NCT01521065 - An Open-label Study to Evaluate the Clinical and Economic Benefits of I-Ray in Patients With Choroidal Neovascularization Secondary to Age-related Macular Degeneration Phase 2
Completed NCT04919473 - Dose-Escalation Study to Evaluate the Safety and Tolerability of Intravitreal vMCO-I in Patients With Advanced Retinitis Pigmentosa Phase 1/Phase 2
Completed NCT01205035 - High-Dose Lucentis (Ranibizumab 2.0mg) for the Treatment of Nonproliferative Idiopathic Parafoveal Telangiectasia Phase 2
Terminated NCT01225146 - Study of 2.0 mg Ranibizumab in Subjects With Ischemic Central Retinal Vein Occlusion (RAVE2) Phase 1
Completed NCT00812760 - Effect of Levodopa on Human Multifocal Electroretinogram Phase 4
Active, not recruiting NCT06071546 - Clinical Investigation of a New Version of MAIA Microperimeter on Healthy Subjects and Patients With Retinal Pathology N/A
Completed NCT02946879 - Long-Term Follow-Up Gene Therapy Study for Leber Congenital Amaurosis OPTIRPE65 (Retinal Dystrophy Associated With Defects in RPE65)
Completed NCT01016873 - INTREPID - IRay Plus Anti-VEGF Treatment For Patients With Wet AMD Phase 2
Recruiting NCT04592068 - AI Classifies Multi-Retinal Diseases
Completed NCT01746563 - Intravitreal Ranibizumab Combined With Panretinal Photocoagulation in Patients With Proliferative Diabetic Retinopathy Phase 1/Phase 2
Completed NCT01399515 - Efficacy and Safety of Oral Valproic Acid for Retinitis Pigmentosa Phase 2
Terminated NCT02348359 - X-82 to Treat Age-related Macular Degeneration Phase 2
Completed NCT03954626 - Study to Collect Safety and ECG Data on Brolucizumab 6 mg Intravitreal Treatment in Patients With Wet AMD Phase 3
Completed NCT02582164 - Long-Working Distance OCT for Children N/A
Completed NCT01790958 - Microcurrent Stimulation to Treat Macular Degeneration N/A
Recruiting NCT05283941 - Pistachios and Neural Macular Pigment N/A
Completed NCT04678375 - Artificial Intelligence for Detecting Retinal Diseases
Completed NCT04902170 - Long-shaft Vitrectomy Probe in Highly Myopic Eyes N/A
Completed NCT02543229 - Study Evaluating the Safety, Pharmacokinetics and Pharmacodynamics of OPT-302 With or Without Lucentis™ in Patients With Wet AMD Phase 1